Clinical bottom line
Infections remain a leading cause of morbidity and mortality in solid organ transplant (SOT) recipients undergoing immunosuppressive therapy. Effective clinical management requires vigilant infection surveillance, early diagnosis, and tailored antimicrobial strategies that consider drug interactions and immunosuppressive regimens. Cytomegalovirus (CMV) and fungal infections, including cryptococcosis, pose significant risks, necessitating prophylaxis and prompt treatment. Emerging data highlight the impact of community-acquired respiratory viruses and the challenges of medication noncompliance, particularly in pediatric populations. Multidisciplinary approaches and individualized care plans are essential to optimize outcomes.
What the evidence shows
Immunosuppressive therapy, critical for graft survival, predisposes SOT patients to a broad spectrum of infections. Fernández et al. (2025) emphasize the importance of recognizing CMV infection in immunocompromised ICU patients, noting its association with increased morbidity and the need for early antiviral intervention.
Cryptococcosis is a serious fungal infection in SOT recipients. Baddley et al. (2019) provide comprehensive guidelines from the American Society of Transplantation Infectious Diseases Community of Practice, recommending risk stratification, diagnostic vigilance, and antifungal management tailored to transplant type and immunosuppressive status.
Drug-drug and drug-food interactions complicate antifungal therapy in transplant recipients. Dodds-Ashley et al. (2010) review management strategies for azole antifungals, highlighting the necessity for careful monitoring to avoid toxicity and subtherapeutic levels.
Pulmonary infections remain common post-transplant. Miller Wallace (2000) details radiologic and clinical features of pulmonary infections in SOT patients, underscoring the need for prompt imaging and microbiologic evaluation to guide therapy.
Marin et al. (2021) discuss immunosuppressive regimens in SOT, emphasizing balancing infection risk with graft rejection prevention. They advocate for personalized immunosuppression adjustments based on infection history and immune monitoring.
Community-acquired respiratory viruses (CARVs) significantly impact SOT patients. Singh et al. (2024) report that CARVs contribute to increased hospitalization and graft dysfunction, supporting the integration of viral surveillance and preventive measures such as vaccination.
Noncompliance with immunosuppressive medications is a critical issue, especially in pediatric and adolescent patients. Rianthavorn et al. (2004) identify nonadherence as a risk factor for rejection and infection, highlighting the need for targeted interventions to improve adherence.
Caveats and uncertainty
Much of the evidence derives from observational studies and expert consensus, with limited randomized controlled trials addressing infection management specifically in SOT populations.
Heterogeneity in transplant types, immunosuppressive protocols, and patient comorbidities complicates standardized infection prevention and treatment approaches.
The evolving landscape of emerging pathogens and antiviral resistance requires ongoing surveillance and guideline updates.
Data on long-term outcomes of novel immunosuppressive agents and their infection risks remain limited.
Noncompliance studies are often limited by self-reporting bias and variable definitions.
How this may change practice
Clinicians should maintain high vigilance for CMV and fungal infections in SOT recipients, employing early diagnostic testing and prophylaxis guided by current guidelines.
Careful management of drug interactions, particularly with azole antifungals, is essential to optimize therapeutic efficacy and minimize toxicity.
Routine screening and preventive strategies for community-acquired respiratory viruses should be incorporated into transplant care protocols.
Immunosuppressive regimens may require individualized adjustments based on infection risk and immune function monitoring.
Addressing medication adherence through patient education and support programs, especially in pediatric populations, can reduce infection and rejection risks.
Multidisciplinary collaboration among transplant surgeons, infectious disease specialists, pharmacists, and nursing staff is critical to comprehensive infection management.